Immobilization resulting from chronic medical diseases: A new risk factor for recurrent venous thromboembolism in anticoagulated patients [3]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 8, 2007, Pages 1786-1787

  Prandoni, Paolo ^a   Villalta, S ^a   Tormene, D ^a   Spiezia, L ^a   Pesavento, R ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANTICOAGULATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HUMAN; IMMOBILIZATION; INTERNATIONAL NORMALIZED RATIO; LETTER; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG VENTILATION PERFUSION RATIO; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTPATIENT; PHLEBOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SYMPTOM;

AGED; ANTICOAGULANTS; CHRONIC DISEASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MIDDLE AGED; RECURRENCE; RESTRAINT, PHYSICAL; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 34447649725     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02645.x     Document Type: Letter

References (10)

1. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 401-28S.
2. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-88.
3. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
4. Monreal M, Falga C, Valdes M, Suarez C, Gabriel F, Tolosa C, Montes J, Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: Findings from the RIETE registry. J Thromb Haemost 2006; 4: 1950-6.
5. Nijkeuter M, Sohne M, Tick LW, Kamphuisen PW, Kramer MH, Laterveer L, van Houten AA, Kruip MJ, Leebeek FW, Buller HR, Huisman MV. The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. Chest 2007; 131: 517-23.
6. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-8.
7. Partsch H. Ambulation and compression after deep vein thrombosis: dispelling myths. Semin Vasc Surg 2005; 18: 148-52.
8. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin vs. a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
9. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002; 162: 1729-35.
10. Dranitsaris G, Vincent M, Crowther M. Dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics 2006; 24: 593-607.